Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2011 2
2012 2
2013 6
2014 3
2015 4
2016 3
2017 2
2019 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Acquired Resistance to Antibody-Drug Conjugates.
Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Collins DM, et al. Among authors: niederfellner g. Cancers (Basel). 2019 Mar 20;11(3):394. doi: 10.3390/cancers11030394. Cancers (Basel). 2019. PMID: 30897808 Free PMC article. Review.
Response to: monoclonal antibodies targeting CD20.
Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G. Klein C, et al. Among authors: niederfellner g. MAbs. 2013 May-Jun;5(3):337-8. doi: 10.4161/mabs.24108. Epub 2013 Mar 14. MAbs. 2013. PMID: 23493087 Free PMC article. No abstract available.
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
Karches CH, Benmebarek MR, Schmidbauer ML, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha BL, Lesch S, Heise C, Murr R, Vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein C, Kobold S. Karches CH, et al. Among authors: niederfellner g. Clin Cancer Res. 2019 Oct 1;25(19):5890-5900. doi: 10.1158/1078-0432.CCR-18-3927. Epub 2019 Jul 8. Clin Cancer Res. 2019. PMID: 31285373 Free PMC article.
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.
Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G. Kollmorgen G, et al. Among authors: niederfellner g. Sci Rep. 2017 Dec 22;7(1):18086. doi: 10.1038/s41598-017-17329-7. Sci Rep. 2017. PMID: 29273809 Free PMC article.
Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death.
Paradisi A, Creveaux M, Gibert B, Devailly G, Redoulez E, Neves D, Cleyssac E, Treilleux I, Klein C, Niederfellner G, Cassier PA, Bernet A, Mehlen P. Paradisi A, et al. Among authors: niederfellner g. EMBO Mol Med. 2013 Dec;5(12):1821-34. doi: 10.1002/emmm.201302654. Epub 2013 Oct 8. EMBO Mol Med. 2013. PMID: 24293316 Free PMC article.
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I. Hassan R, et al. Among authors: niederfellner g. Cancer. 2020 Nov 15;126(22):4936-4947. doi: 10.1002/cncr.33145. Epub 2020 Sep 1. Cancer. 2020. PMID: 32870522 Free PMC article. Clinical Trial.
26 results